RLYB Rallybio Corp
Price Chart
Executive Summary
Rallybio Corp (RLYB) filed this 425 communication to confirm the definitive merger agreement entered into on May 31, 2026, with Avenzo Therapeutics. In the reverse-merger transaction, Avenzo will become a wholly-owned subsidiary of Rallybio, and Rallybio will change its name to Avenzo Therapeutics, Inc. Concurrently, Avenzo secured a $215.0 million PIPE financing. Existing Rallybio shareholders will own approximately 2.8% of the combined company, while pre-Merger Avenzo equityholders (excluding PIPE investors) will own approximately 56.6%, and PIPE investors will own approximately 40.6%.
Actionable Insight
This filing confirms the structure and financing of the reverse merger. The $215M PIPE provides a strong cash runway for the combined oncology-focused entity. Monitor the S-4 filing for the proxy statement and the shareholder vote timeline. The CVRs offer a potential upside from legacy asset sales but are highly speculative.
Key Facts
- Rallybio entered into a definitive merger agreement with Avenzo Therapeutics on May 31, 2026.
- The transaction is a reverse merger where Avenzo will survive as a wholly-owned subsidiary of Rallybio.
- Avenzo raised $215.0 million in a concurrent PIPE financing at closing.
- Pre-Merger Avenzo equityholders (excluding PIPE investors) are expected to own ~56.6% of the combined company.
- Pre-Merger Rallybio equityholders are expected to own ~2.8% of the combined company.
- PIPE investors are expected to own ~40.6% of the combined company.
- Rallybio is valued at $15.0 million and Avenzo at $300.0 million for the exchange ratio calculation.
- Rallybio will distribute its net cash to existing shareholders prior to closing via a pre-closing distribution.
- Existing Rallybio executive officers and directors are expected to resign at closing; Avenzo management will take over.
- Rallybio shareholders will receive contingent value rights (CVRs) tied to potential proceeds from legacy asset sales.
- The merger is subject to shareholder approvals, Nasdaq listing, and other customary closing conditions.
- Avenzo may owe a $20.0 million termination fee to Rallybio in certain circumstances; Rallybio may owe a $600,000 fee to Avenzo.
Financial Impact
Avenzo raised $215.0 million in PIPE financing. Rallybio valued at $15.0 million, Avenzo at $300.0 million. Pre-merger Rallybio shareholders will own ~2.8% of the combined entity.
Risk Factors
- Risk that the merger does not close due to failure to obtain shareholder approvals or other conditions.
- Risk that Rallybio shareholders receive no value from the CVRs if legacy assets are not monetized.
- Risk of shareholder litigation challenging the merger terms.
- Risk that the combined company fails to execute on Avenzo's oncology pipeline.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-249801 |
| Document: 0001193125-26-249801-index-headers.html | 0001193125-26-249801 |
| Document: 0001193125-26-249801-index.html | 0001193125-26-249801 |
| Document: 0001193125-26-249801.txt | 0001193125-26-249801 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
5d ago
|
425
| $16.87 $16.23 | ▼ −3.79% | ▼ −3.94% | $15.95 (−5.45%) |
|
Jun 1, 2026
5d ago
|
8-K
| $16.87 $16.23 | ▼ −3.79% | ▼ −3.94% | $15.95 (−5.45%) |
|
May 4, 2026
4w ago
|
8-K
| $14.12 $14.28 | ▲ +1.13% | ▲ +0.34% | $15.95 (+12.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access